Report

Novo Nordisk oral Wegovy and Eli Lilly orforglipron reportedly set for India in first half of 2027

The Economic Times reports Novo Nordisk’s oral Wegovy and Eli Lilly’s orforglipron are expected in India in the first half of 2027, and that top officials said both products have already been submitted to Indian regulators.

1 Source, 9d ago, first seen 9d ago

TLDR

The Economic Times reports Novo Nordisk’s oral Wegovy and Eli Lilly’s orforglipron are expected to reach India in the first half of 2027. Doctors cited by ET said pills could expand demand among people who avoid injections and some patients seeking maintenance therapy, but pricing may be crucial in India, and ET’s cited efficacy figures for oral drugs were lower than for injectables.

Combined views

7.7K

1 Source, first seen 9d ago

1 likes

Report

Novo Nordisk oral Wegovy and Eli Lilly orforglipron reportedly set for India in first half of 2027

1 Source, 9d ago, first seen 9d ago

TLDR

Today's Rank

—

Not ranked yet

Combined views

7.7K

1 Source, first seen 9d ago

1 likes

Novo Nordisk’s oral Wegovy and Eli Lilly’s oral GLP-1 drug orforglipron are reportedly expected to enter India in the first half of 2027, according to The Economic Times.

Featured Source

ET reported that top officials said both companies have already submitted their oral products to Indian regulators. The paper framed the expected arrivals as a new phase in India’s obesity drug market, with the next contest centered on pills rather than injectable treatments.

Why pills could expand the market

Doctors cited by ET said oral GLP-1 drugs could create two possible pools of demand: patients who have avoided injectable treatment because they fear needles, and people already using weekly shots who may want to switch to pills for longer-term weight maintenance.

The trade-offs ET highlights

ET cites figures saying oral weight loss drugs have average weight-loss efficacy of 12% to 15%, compared with 15% to 22% for injectables.

Price may be just as important in India. ET quotes Mumbai-based diabetologist Neeraj Tulara saying pricing will matter, and reports that a senior official, speaking anonymously, said Novo is aware of the Indian market’s price sensitivity.

ET also attributed a more specific launch sequence to one of the people it cited, reporting that “orforglipron is expected by January-February, followed by oral Wegovy.”

Sentiment

Positive——Negative

Summary

Not enough discussion yet.

No sentiment analysis available yet.

Novo Nordisk oral Wegovy and Eli Lilly orforglipron reportedly set for India in first half of 2027

TLDR

Combined views

Combined views

Novo Nordisk oral Wegovy and Eli Lilly orforglipron reportedly set for India in first half of 2027

TLDR

Combined views

Why pills could expand the market

The trade-offs ET highlights

Sentiment

Summary

2 Sources

Combined views

Sentiment

Summary

Why pills could expand the market

The trade-offs ET highlights

Sentiment

Summary

Sentiment

Summary

2 Sources

2 Sources

2 Sources